波生坦治疗肺动脉高压的疗效观察及临床分析

Therapeutic efficacy and clinical analysis of Bosentan in the treatment of pulmonary hypertension

目的观察特发性肺动脉高压(IPAH)患者接受波生坦治疗4周后的6 min步行距离(6MWD)较基线的改善情况,评估WHO功能分级、超声心动图(UCG)及临床变化和非侵入性血流动力学参数变化。方法住院26例IPAH患者口服波生坦治疗4周,彩色多普勒UCG测量用药前、后患者肺动脉收缩压(sPAP)的变化。结果波生坦能有效地改善肺动脉压,治疗后患者的6 MWD、WHO功能分级、sPAP和UCG指标均较治疗前有显著改善,差异有统计学意义(P<0.05或P<0.01)。波生坦治疗肺动脉高压不良反应发生率低。结论波生坦治疗可以提高肺动脉高压患者的运动能力,改善心功能和呼吸困难的症状,是治疗IPAH安全有效的药物。

Objective To observe the improvement of 6-minute walking distance of idiopathic pulmonary hypertension （I PAH） patients after four weeks＂ Bosentan treatment compared with baseline, and evaluate the WHO function classification, ultrasound cardiogram （UCG）, clinical changes and non-invasive hemodynamic parameters change. Methods 26 cases of I- PAH patients were treated with Bosentan for 4 weeks. Color doppler UCG was used to measure the changes of systolic pul- monary artery pressure （sPAP） before and after treatment. Results Bosentan can effectively improve the pulmonary artery pressure. Compared with pre-treatment, after treatment the indicators of 6MWD, WHO function classification, sPAP and UCG were significant differences （P 〈 0.05 or P 〈 0.01）. The adverse reaction of Bosentan in the treatment of pulmonary hypertension was low. Conclusion Bosentan treatment can improve IPAH patients＂ athletic ability, improve cardiac func- tion and difficulty breathing symptoms. Bosentan is a safe and effective drug in the treatment of IPAH.